BAJAJ FINSERV DIRECT LIMITED
Open Your FREE Demat Account Now!

Akums Drugs & Pharmaceuticals Ltd. Share Price

NSE
BSE

NSE : AKUMS

BSE : 544222

Sector : Healthcare

N/A
indicator
1D
1M
3M
6M
1Y
5Y
empty graph

Day's Range

Day's Range

Low

₹545.00

High

₹560.00

Price Summary

Previous Close ₹548.00
Day's Range ₹545.00 - ₹560.00
Open ₹555.90
52 Week Range ₹409.30 - ₹622.95
Volume 1,08,188
Market Cap ₹0.01
Previous Close ₹547.35
Day's Range ₹546.20 - ₹558.80
Open ₹555.40
52 Week Range ₹410.10 - ₹620.00
Volume 4,855
Market Cap ₹0.01

Stocks Summary

Trade Value ( ₹ in Lacs) 592.87
Market Cap (₹ in Mn) 0.01
Dividend Yield(%) 0.00
Price/Earning (TTM) 27.12
TTM EPS (₹) 20.22
P/E Ratio 21.49
Book Value(₹) 2.68
PAT Margin (%) 8.35
Face Value (₹) 2.00
ROCE(%) 17.83
Trade Value ( ₹ in Lacs) 26.57
Market Cap (₹ in Mn) 0.01
Dividend Yield(%) 0.00
Price/Earning (TTM) 27.12
TTM EPS (₹) 20.22
P/E Ratio 21.49
Book Value(₹) 2.68
PAT Margin (%) 8.35
Face Value (₹) 2.00
ROCE(%) 17.83

Financials

Particulars QTR FY (₹ in Millions) Annual FY (₹ in Millions)
Net sales 3374.07 14441.19
Expenses N/A N/A
PBT 548.91 -1029.33
Operating profit 0.0 0.0
Net profit 411.68 -1654.51

Shareholding Pattern

Promoters (% Holding)

75.26%

Mutual funds (% Holding)

10.95%

Non-Institution (% Holding)

9.02%

FI/Banks/Insurance (% Holding)

0.60%

Government (% Holding)

0.00%

FII

1.38%

About Akums Drugs & Pharmaceuticals Ltd.

Founded 2004
Managing Director Sanjeev Jain
NSE Symbol AKUMS

Peer Comparision

Stocks Name Market Cap (Cr)(₹) Market Price (₹) 52 Week Low-High (₹)
Sun Pharmaceutical Industries Ltd. 4,40,134.01 1,831.30 1,548.00 - 1,548.00
Divi's Laboratories Ltd. 1,77,883.86 6,681.00 5,636.50 - 5,636.50
Torrent Pharmaceuticals Ltd. 1,47,526.68 4,351.60 3,101.60 - 3,101.60
Apollo Hospitals Enterprise Ltd. 1,12,696.26 7,820.45 6,677.50 - 6,677.50
Lupin Ltd. 1,12,463.67 2,460.50 1,836.80 - 1,836.80
Cipla Ltd. 1,10,088.66 1,361.00 1,165.70 - 1,165.70
Dr. Reddy's Laboratories Ltd. 1,09,072.97 1,307.00 1,138.50 - 1,138.50
Max Healthcare Institute Ltd. 98,793.98 1,015.10 903.00 - 903.00
Mankind Pharma Ltd. 98,063.24 2,375.40 1,909.70 - 1,909.70
Zydus Lifesciences Ltd. 94,596.06 940.10 835.50 - 835.50
no-content No Records Found

Latest News

Apr
4
2026
EQUITY Posted on Apr 4th 2026

Akums Drugs and Pharmaceuticals informs about certificate

Akums Drugs and Pharmaceuticals has informed that it enclosed a copy of the Certificate received from MUFG Intime India, the Registrar & Share Transfer Agent (RTA) of the Company, confirming the compliance of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 31st March, 2026.

The above information is a part of company’s filings submitted to BSE.

Read More
Feb
19
2026
EQUITY Posted on Feb 19th 2026

Akums Drugs and Pharmaceuticals informs about transcript of earnings call

Pursuant to the Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) 2015, Akums Drugs and Pharmaceuticals has informed that it enclosed the transcript of earnings/analyst conference call held on Monday, February 16, 2026 at 12:00 PM (IST) on Un-audited financial results for Q3 of FY26. The said transcript be also available on the Company’s website https://www.akums.in/investors/investors-meet/.
The above information is a part of company’s filings submitted to BSE. 
Read More
May
7
2026
EQUITY Posted on May 7th 2026

Global Longlife Hospital and Research informs about outcome of board meeting

In compliance with Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Global Longlife Hospital and Research has informed that in the Board Meeting held today on Thursday, May 07, 2026, the Board of Directors of the Company has considered and approved the following matters: 1. Audited Financial Results for the Half Year and Year ended March 31, 2026 along with the Audit Report. 2. Alteration of name clause of Memorandum of Association of the company from Global Longlife Hospital and Research to Kanzi Enterprise or Asahi Enterprise or Siddhaa Enterprise, subject to the approval of shareholders of the company and ministry of corporate affairs. 3. Alteration in Clause III (A): the Main Object Clause of Memorandum of Association (‘MOA’) of the Company, subject to approval of Members. (The existing Clause III (A) will be deleted representing health care industry and new Clause III (A) will be added representing trade and service industry). The above matter has been duly approved by the Board of Directors at their meeting which commenced at 02:00 pm and concluded at 03:45 pm. The company has informed that, R B Gohil & Co., Chartered Accountants, Statutory Auditors have issued their Audit Reports with unmodified opinion on Audited Financial Results for the year ended March 31, 2026. In this connection, it has enclosed Audited Financial Results for the Half year and Year ended on March 31, 2026, Audit Report and the declaration that Auditor's Report on the results is with unmodified opinion (as Annexure-1). The same will be made available on the Company's website www.globalhospital.co.in.
The above information is a part of company’s filings submitted to BSE.
Read More
May
7
2026
EQUITY Posted on May 7th 2026

Panacea Biotec informs about updates

Panacea Biotec has informed that it enclosed details of shares dematerialised during April 2026 under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.
The above information is a part of company’s filings submitted to BSE.
Read More
May
7
2026
EQUITY Posted on May 7th 2026

Kilitch Drugs India informs about board meeting

Kilitch Drugs India has informed that the meeting of the Board of Directors of the Company is scheduled on 15/05/2026 to consider and approve the audited financial results (standalone and consolidated) of the Company for the quarter and year ended 31st March, 2026.
The above information is a part of company’s filings submitted to BSE.
Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Frequently Asked Questions

What is the current share price of Akums Drugs & Pharmaceuticals Ltd. ?

The current share price of Akums Drugs & Pharmaceuticals Ltd. is ₹548.00 as of 2026-05-07.

The market capitalisation of Akums Drugs & Pharmaceuticals Ltd. is ₹8,629.91 as of 2026-05-07.

The 1-year return of Akums Drugs & Pharmaceuticals Ltd. is 0.00% as of 2026-05-07.

The P/E ratio of Akums Drugs & Pharmaceuticals Ltd. is 21.49 as of 2026-05-07.

The 52-week high and low of Akums Drugs & Pharmaceuticals Ltd. are ₹622.95 and ₹409.30, respectively, as of 2026-05-07.

The dividend yield of Akums Drugs & Pharmaceuticals Ltd. is 0.0% as of2026-05-07.

You can buy Akums Drugs & Pharmaceuticals Ltd. shares through a registered stockbroker or trading platform. Bajaj Markets partners with trusted brokers to help you open a demat account. This is the first step to trading, making it easier to invest in your desired shares.

The Managing Director of Akums Drugs & Pharmaceuticals Ltd. is Sanjeev Jain.

When investing in a company’s stock, you may consider key factors such as its fundamentals, including financial health, historical performance, and growth potential. Assess the consistency of its performance, market conditions, and industry trends. Additionally, evaluate your own risk tolerance while reviewing aspects like quarterly earnings, management quality, and sector performance, for taking a well-informed decision.

You can track stock performance on online platforms through live market updates, historical charts, and news alerts. Regular analysis and stock alerts allow you to stay informed about significant price changes and events affecting the stock.

Common stock provides voting rights and the potential for dividends based on company performance, while in case of preferred stock, stockholders receive fixed dividends and have priority over common stockholders in asset distribution but generally lack voting rights.

Stock investments carry market risks, including price volatility, economic shifts, and sector-specific issues. Managing risk can involve diversifying your portfolio, setting stop-loss orders, and staying informed about market trends to make timely decisions.

Market capitalisation, or market cap, is the total value of a company’s outstanding shares and is calculated by multiplying the stock price by the total shares. It classifies companies as large-cap, mid-cap, or small-cap, reflecting their size, stability, and potential risk level in the stock market.

View More

Disclaimer

This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Personal Loan
My Accounts
My Accounts
Explore
Explore